ArticleJournal of the American Heart Association2017
CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage.
Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Neuroprotective effect of small extracellular vesicle-mediated targeting of AMPKα2 in cerebral ischemia.Metabolism: clinical and experimental · 2025Article
- Blood Progenitor Cell Mobilization Driven by TWEAK Promotes Neovascularization and Reduces Brain Damage in a Rat Model of Intracerebral Hemorrhage.Antioxidants (Basel, Switzerland) · 2025Article
- The role of MMPs in intracerebral hemorrhage.Frontiers in cell and developmental biology · 2025Review
- Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Neuroprotection Afforded by an Enriched Mediterranean-like Diet Is Modified by Exercise in a Rat Male Model of Cerebral Ischemia.Antioxidants (Basel, Switzerland) · 2024Article
- Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.Journal of nanobiotechnology · 2024Article
- CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage.Thrombosis and haemostasis · 2022Article
- miR-30e-5p attenuates neuronal deficit and inflammation of rats with intracerebral hemorrhage by regulating TLR4.Experimental and therapeutic medicine · 2022Article
- Sonosensitive capsules for brain thrombolysis increase ischemic damage in a stroke model.Journal of nanobiotechnology · 2022Article
- Increasing miR-126 Can Prevent Brain Injury after Intracerebral Hemorrhage in Rats by Regulating ZEB1.Contrast media & molecular imaging · 2022Article
- Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage.Scientific reports · 2020Article
- Matrix Metalloproteinases in Acute Intracerebral Hemorrhage.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- miR‑222 regulates brain injury and inflammation following intracerebral hemorrhage by targeting ITGB8.Molecular medicine reports · 2020Article
- Hematoma Expansion in Intracerebral Hemorrhage: An Update on Prediction and Treatment.Frontiers in neurology · 2020Review
- MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes.Translational stroke research · 2019Article
- Treatment of secondary brain injury by perturbing postsynaptic density protein-95-NMDA receptor interaction after intracerebral hemorrhage in rats.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Article
- Inflammatory Profiles of the Interleukin Family and Network in Cerebral Hemorrhage.Cellular and molecular neurobiology · 2018Review
- Inflammation, edema and poor outcome are associated with hyperthermia in hypertensive intracerebral hemorrhages.European journal of neurology · 2018Article
- Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.ACS medicinal chemistry letters · 2018Article
- Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Protects Against Neuronal Apoptosis via Activation of Akt/MDM2/p53 Signaling Pathway in a Rat Model of Intracerebral Hemorrhage.Frontiers in molecular neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracerebral hemorrhage (ICH) is an acute neurological disorder with high mortality and no effective treatment. In addition to the initial bleeding event, rebleeding and hematoma expansion are associated with poor outcome in these patients. We studied the effectiveness of the new antifibrinolytic agent CM352, a short-half-life matrix metalloproteinase inhibitor, for achieving early hemostasis and improving functional recovery in a rat model of collagenase-induced ICH. METHODS AND
resultsICH was induced by striatal injection of collagenase, and 1 hour later, rats received an intravenous injection of saline (n=6) or CM352 (1 mg/kg, n=6). Hematoma (basal and after 3 and 24 hours) and lesion (14 days) volumes were quantified on T2-weighted (T2) magnetic resonance images. Neurological and functional recovery was evaluated by using Bederson score and a cylinder test (basal, 24 hours, and 14 days). Early treatment (1 hour) with CM352 was efficient reducing hematoma expansion at 3 hours (
conclusionsCM352, a new antifibrinolytic agent and matrix metalloproteinase inhibitor, effectively prevented hematoma growth and reduced lesion size in ICH in association with improved functional and neurological recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.